Interferon-β now can be regarded as an established disease modifying agent in relapsing remitting and secondary progressive MS as shown unequivocally in several well designed studies conducted by different pharmaceutical companies. Glatiramer acetate is also effective in relapsing remitting MS, although thi...
Alternatives to current disease-modifying treatment in MS: what do we need and what can we expect in the future? J. Neurol. 251, 57-64.Kappos L, Kuhle J, Gass A, Achtnichts L, Radus E-W. Alternatives to current disease-modifying treatments in MS: what do we need and what can we ...
Time to EDSS6 was similar for the treatment strategies respectively: 14.6 vs 16.4 vs 13.3 years, p=0.13. Conclusions Patients requiring escalation had relatively worse outcomes, and could be identified as having higher disease activity on treatment initiation. This data suggest that initial selection...
Disease-modifying treat- ments for multiple sclerosis: a review of approved medications. Eur J Neurol 2015;23(suppl 1):18-27.Torkildsen, O, Myhr, K-M, BO, L., 2015. Disease- Modifying Treatments for Multiple Sclerosis - A Review of Approved Medications. European Journal of Neurol., 23 ...
MS is characterized by formation of white matter lesions in the CNS as a result of inflammation, demyelination, and axonal loss. Treatment has been a focus of neurological research for over 60鈥厃ears. A number of disease-modifying therapies (DMTs) have become available making MS ...
Most MS Disease modifying treatments (DMT) are available in UAE. While UAE has a medical regulatory authority, its role has not yet extended into appraisals of individual medicines or cost effectiveness. Therefore, adoption of recommendations by the Food and Drug Administration(FDA) or European ...
Further understanding of the early events in pathogenesis is also needed to develop preventive and disease-modifying treatments. KD Stone,C Prussin - 《Clinical & Experimental Allergy》 被引量: 119发表: 2010年 An Electrochemical Detection of Metallothioneins at the Zeptomole Level in Nanolitre Volumes...
Multiple sclerosis (MS) is a chronic immune-mediated demyelinating and neurodegenerative disease, and the main disease-modifying treatments rely on modulation or suppression of the immune system Current results show that most drugs to treat MS are linked to an increased risk of infection to varying ...
EP: 6.Criteria for Diagnosing Alzheimer Disease and the Role of Testing EP: 7.Exploring the Economic Impact of Advanced Approaches for Diagnosing Alzheimer Disease Now Viewing EP: 8.Clinical Impact of the Introduction of Disease-Modifying Treatments for Alzheimer Disease ...
New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis. Interferon injectables and glatiramer acetate have served as the primary disease-modifying treatments for multiple sclerosis (MS) since their introduction ... C English,JJ Aloi - 《Clinical Therapeutics》 被引量: 79发表: 2015年 Earl...